Literature DB >> 25605150

Epidermal growth factor receptor mutations in Japanese men with lung adenocarcinomas.

Masaki Tomita1, Takanori Ayabe, Eiichi Chosa, Katsuya Kawagoe, Kunihide Nakamura.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations play a vital role in the prognosis of patients with lung adenocarcinoma. Such somatic mutations are more common in women who are non-smokers with adenocarcinoma and are of Asian origin. However, to our knowledge, there are few studies that have focused on men.
MATERIALS AND METHODS: One hundred and eighty-four consecutive patients (90 men and 94 women) of resected lung adenocarcinoma were studied retrospectively.
RESULTS: EGFR mutations were positive in 48.9% and negative (wild type) in 51.1%. Overall mutation was significant in women (66.0% vs. 32.2%) compared with men (p<0.001). For overall patients, EGFR mutation status was associated with gender, pStage, pT status, lepidic dominant histologic subtype, pure or mixed ground-glass nodule type on computed tomography and smoking status. However, in men, EGFR mutation status was only associated with lepidic dominant histologic subtype and not the other variables. Interestingly, the Brinkman index of men with mutant EGFR also did not differ from that for the wild type (680.0±619.3 vs. 813.1±552.1 p=0.1077).
CONCLUSIONS: The clinical characteristics of men with lung adenocarcinoma related to EGFR mutation are not always similar to that of overall patients. Especially we failed to find the relationship between EGFR mutations and smoking status in men.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25605150     DOI: 10.7314/apjcp.2014.15.24.10627

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

Review 1.  Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.

Authors:  Roberto Chalela; Víctor Curull; César Enríquez; Lara Pijuan; Beatriz Bellosillo; Joaquim Gea
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

2.  Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics.

Authors:  Ali Sabri; Madiha Batool; Zhaolin Xu; Drew Bethune; Mohamed Abdolell; Daria Manos
Journal:  Eur Radiol       Date:  2016-03-30       Impact factor: 5.315

3.  EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?

Authors:  Xiaoyi Qin; Xiaolong Gu; Yingru Lu; Wei Zhou
Journal:  Cancer Manag Res       Date:  2018-10-01       Impact factor: 3.989

4.  Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis.

Authors:  Zihan Wei; Ziyang Wang; Yuntao Nie; Kai Zhang; Haifeng Shen; Xin Wang; Manqi Wu; Fan Yang; Kezhong Chen
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

5.  Development and Validation of a Concise Prediction Scoring System for Asian Lung Cancer Patients with EGFR Mutation Before Treatment.

Authors:  Wenting An; Wei Fan; Feiyang Zhong; Binchen Wang; Shan Wang; Tian Gan; Sufang Tian; Meiyan Liao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Expression and prognostic value of GalNAc-T3 in patients with completely resected small (≤2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.

Authors:  Shilei Zhao; Tao Guo; Jinxiu Li; Hidetaka Uramoto; Hongwei Guan; Wuguo Deng; Chundong Gu
Journal:  Onco Targets Ther       Date:  2015-10-27       Impact factor: 4.147

Review 7.  Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Authors:  Lei-Yun Wang; Jia-Jia Cui; Ao-Xiang Guo; Ji-Ye Yin
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.